

CITATION REPORT

List of articles citing

Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century

DOI: 10.1016/j.ijantimicag.2007.05.015

International Journal of Antimicrobial Agents, 2007, 30, 297-308.

Source: <https://exaly.com/paper-pdf/42406768/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
305	Development and in vitro evaluation of chloroquine gels as microbicides against HIV-1 infection. 2008 , 378, 306-10		12
304	Editorial International Journal of Antimicrobial Agents - Volume 31, Issue 1. <i>International Journal of Antimicrobial Agents</i> , 2008 , 31, 1-2	14.3	47
303	Simulating henipavirus multicycle replication in a screening assay leads to identification of a promising candidate for therapy. 2009 , 83, 5148-55		60
302	Efficacy of a long-term antibiotic treatment in patients with a chronic Tick Associated Poly-organic Syndrome (TAPOS). 2009 , 39, 108-15		9
301	Predictors of major infections in systemic lupus erythematosus. 2009 , 11, R109		222
300	Therapy: Hydroxychloroquine in SLE: old drug, new perspectives. 2010 , 6, 10-1		31
299	Bepidil and amiodarone simultaneously target the Alzheimer's disease beta- and gamma-secretase via distinct mechanisms. 2010 , 30, 8974-83		44
298	Chloroquine and its derivatives exacerbate B19V-associated anemia by promoting viral replication. 2010 , 4, e669		19
297	A new role for antimalarials in systemic lupus erythematosus treatment. 2010 , 5, 299-312		1
296	Antimalarials and SLE. 2011 , 1061-1081		0
295	Protein glycosylation in infectious disease pathobiology and treatment. 2011 , 6, 802		8
294	Discovering thiamine transporters as targets of chloroquine using a novel functional genomics strategy. 2012 , 8, e1003083		18
293	OC-140 Hydroxychloroquine as a treatment for crohn's disease: enhancing antibiotic efficacy and macrophage killing of E coli. 2012 , 61, A60.2-A61		2
292	OC-141 Upper GI bleeding in Scotland 2000-2010: improving outcome but a significant weekend effect. 2012 , 61, A61.1-A61		
291	Antimalarial drug chloroquine counteracts activation of indoleamine (2,3)-dioxygenase activity in human PBMC. 2012 , 2, 241-5		14
290	Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis. 2012 , 64, 3083-94		317
289	Hydroxychloroquine: from malaria to autoimmunity. 2012 , 42, 145-53		348

288	Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. 2013 , 22, 1286-94	205
287	Kaposi's sarcoma: etiology and pathogenesis, inducing factors, causal associations, and treatments: facts and controversies. 2013 , 31, 413-422	76
286	Antimalarial Medications. 2013 , 601-608	3
285	Multifaceted effects of hydroxychloroquine in human disease. 2013 , 43, 264-72	88
284	Activity of antimalarial drugs in vitro and in a murine model of cutaneous leishmaniasis. 2013 , 62, 1001-1010	13
283	Perioperative Management of Patients with Rheumatic Disease. 2013 ,	2
282	Cell wall perturbation sensitizes fungi to the antimalarial drug chloroquine. 2013 , 57, 3889-96	23
281	Lymphopenia as risk factor for development of severe infections in patients with systemic lupus erythematosus: a case-control study. 2013 , 106, 451-7	47
280	Rhombencephalitis caused by Francisella tularensis. 2013 , 51, 3454-5	6
279	First Case of Bartonella henselae Bacteremia in Korea. 2013 , 45, 446-50	9
278	A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. 2013 , 8, e60579	196
277	In vitro Synergism between Chloroquine and Antibiotics against Orientia tsutsugamushi. 2014 , 46, 182-8	5
276	Abnormal weight gain and gut microbiota modifications are side effects of long-term doxycycline and hydroxychloroquine treatment. 2014 , 58, 3342-7	65
275	Xenophagy in Helicobacter pylori- and Epstein-Barr virus-induced gastric cancer. 2014 , 233, 103-12	22
274	Chloroquine interferes with dengue-2 virus replication in U937 cells. 2014 , 58, 318-26	55
273	Signaling of chloroquine-induced stress in the yeast Saccharomyces cerevisiae requires the Hog1 and Slr2 mitogen-activated protein kinase pathways. 2014 , 58, 5552-66	12
272	Interplay of infections, autoimmunity, and immunosuppression in systemic lupus erythematosus. 2014 , 33, 330-63	40
271	Development, validation and clinical application of a LC-MS/MS method for the simultaneous quantification of hydroxychloroquine and its active metabolites in human whole blood. 2014 , 100, 131-137	23

270	Hydroxychloroquine: a multifaceted treatment in lupus. 2014 , 43, e167-80	101
269	Opportunistic Pathogens in Inflammatory Bowel Disease,. 2014 , 229-237	
268	Impact of Hydroxychloroquine-Loaded Polyurethane Intravaginal Rings on Lactobacilli. 2015 , 59, 7680-6	19
267	Evaluation of Ebola Virus Inhibitors for Drug Repurposing. 2015 , 1, 317-26	164
266	Antiviral activity of chloroquine against dengue virus type 2 replication in Aotus monkeys. 2015 , 28, 161-9	48
265	Evaluation of Crimean-Congo hemorrhagic fever virus in vitro inhibition by chloroquine and chlorpromazine, two FDA approved molecules. 2015 , 118, 75-81	31
264	Infectious disease. Combating emerging viral threats. 2015 , 348, 282-3	131
263	Doxycycline assay hair samples for testing long-term compliance treatment. 2015 , 71, 511-7	9
262	Critical review of studies trying to evaluate the treatment of chronic Lyme disease. 2015 , 44, 828-31	4
261	Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action?. 2015 , 34, 661-8	19
260	Synergistic activity of chloroquine with fluconazole against fluconazole-resistant isolates of <i>Candida</i> species. 2015 , 59, 1365-9	15
259	Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients. 2016 , 88, 2170-2178	25
258	Towards antiviral therapies for treating dengue virus infections. 2016 , 30, 1-7	41
257	Fungistatic effect of hydroxychloroquine, lessons from a case. 2016 , 13, 17-18	6
256	Chloroquine inhibits lytic replication of Kaposi's sarcoma-associated herpesvirus by disrupting mTOR and p38-MAPK activation. 2016 , 133, 223-33	15
255	New use of an old drug: chloroquine reduces viral and ALT levels in HCV non-responders (a randomized, triple-blind, placebo-controlled pilot trial). 2016 , 94, 613-9	30
254	The putative phospholipase Lip2 counteracts oxidative damage and influences the virulence of <i>Ustilago maydis</i> . 2017 , 18, 210-221	4
253	Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. 2017 , 47, 38-45	80

252	Antiviral Drugs and Other Therapeutic Options for Dengue Virus Infection. 2017 , 9, 185-193	2
251	Prevention of Infection in Lupus Patients. 2017 , 03,	
250	Tuberculosis and systemic lupus erythematosus: a case-control study in Mexico City. 2018 , 37, 2095-2102	7
249	New use for an old treatment: Hydroxychloroquine as a potential treatment for systemic vasculitis. 2018 , 17, 660-664	21
248	The subgingival microbiome in patients with established rheumatoid arthritis. 2018 , 57, 1162-1172	20
247	Implant delivering hydroxychloroquine attenuates vaginal T lymphocyte activation and inflammation. 2018 , 277, 102-113	10
246	Simultaneous quantitation of hydroxychloroquine and its metabolites in mouse blood and tissues using LC-ESI-MS/MS: An application for pharmacokinetic studies. 2018 , 1072, 320-327	45
245	Drug repurposing approaches to fight Dengue virus infection and related diseases. 2018 , 23, 997-1019	32
244	Antiviral Activity of Novel Quinoline Derivatives against Dengue Virus Serotype 2. 2018 , 23,	43
243	Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. 2018 , 38, 653-671	152
242	Potentiating bacterial cancer therapy using hydroxychloroquine liposomes. 2018 , 280, 39-50	11
241	Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort. 2019 , 28, 1101-1110	26
240	Antimalarial Medications. 2019 , 650-660	
239	Shared gut, but distinct oral microbiota composition in primary Sjögren's syndrome and systemic lupus erythematosus. 2019 , 97, 77-87	72
238	Prevention of infections in patients with antineutrophil cytoplasm antibody-associated vasculitis: potential role of hydroxychloroquine. 2020 , 79, e19	1
237	Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage. 2020 , 86, 39-49	9
236	Update of the current knowledge on genetics, evolution, immunopathogenesis, and transmission for coronavirus disease 19 (COVID-19). 2020 , 16, 2906-2923	20
235	Global impacts of pre- and post-COVID-19 pandemic: Focus on socio-economic consequences. 2020 , 1, 100042	23

234	Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. 2020 , 216, 107672	31
233	Assessment of Chloroquine and Hydroxychloroquine Safety Profiles: A Systematic Review and Meta-Analysis. 2020 , 11, 562777	7
232	Hydroxy-chloroquine to treat COVID-19 - infected patients: Some lessons from medical anthropology and history of medicine. 2020 , 15, 100587	
231	Novel corona virus (COVID-19) pandemic: current status and possible strategies for detection and treatment of the disease. 2020 , 1-24	11
230	The C-C Chemokine Receptor Type 4 Is an Immunomodulatory Target of Hydroxychloroquine. 2020 , 11, 1253	1
229	Interaction of Hydroxychloroquine with Pharmacokinetically Important Drug Transporters. 2020 , 12,	4
228	SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings. 2020 , 9,	23
227	Systemic lupus erythematosus and infections. 2020 , 72, 154-169	2
226	Update on recommendations for the diagnosis and treatment of SARS-CoV-2 infection in children. 2020 , 39, 2211-2223	6
225	Ultrarapid diagnosis, microscope imaging, genome sequencing, and culture isolation of SARS-CoV-2. 2020 , 39, 1601-1603	27
224	What to expect from different drugs used in the treatment of COVID-19: A study on applications and in vivo and in vitro results. 2020 , 887, 173467	12
223	A Review on Currently Available Potential Therapeutic Options for COVID-19. 2020 , 13, 443-467	11
222	Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials. 2020 , 21,	27
221	Neutrophil Extracellular Traps (NETs) and Damage-Associated Molecular Patterns (DAMPs): Two Potential Targets for COVID-19 Treatment. 2020 , 2020, 7527953	87
220	DEVELOPMENT AND CLINICAL EVALUATION OF TOPICAL HYDROQUINONE NIOSOMAL GEL FORMULATION FOR THE TREATMENT OF MELASMA. 2020 , 228-236	1
219	Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19. 2020 , 15, 2085-2102	36
218	Antimalarials as Antivirals for COVID-19: Believe it or Not!. 2020 , 360, 618-630	14
217	Theoretical Insights into the Anti-SARS-CoV-2 Activity of Chloroquine and Its Analogs and In Silico Screening of Main Protease Inhibitors. 2020 , 19, 4706-4717	9

216	Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case for Antimalarial Aminoquinolines. 2020 , 11, 2159	6
215	Smoking and COVID-19: Adding Fuel to the Flame. 2020 , 21,	31
214	Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. 2020 , 585, 588-590	243
213	What are the drugs having potential against COVID-19?. 2020 , 1-21	4
212	Therapeutic Strategies in the Development of Anti-viral Drugs and Vaccines Against SARS-CoV-2 Infection. 2020 , 57, 4856-4877	20
211	New Anti SARS-Cov-2 Targets for Quinoline Derivatives Chloroquine and Hydroxychloroquine. 2020 , 21,	15
210	PB28, the Sigma-1 and Sigma-2 Receptors Modulator With Potent Anti-SARS-CoV-2 Activity: A Review About Its Pharmacological Properties and Structure Affinity Relationships. 2020 , 11, 589810	11
209	SARS-CoV-2: A critical review of its history, pathogenesis, transmission, diagnosis and treatment. 2020 , 2, 217-225	12
208	Combating devastating COVID-19 by drug repurposing. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 105984	14-3 42
207	Clinical trials on drug repositioning for COVID-19 treatment. 2020 , 44, e40	226
206	Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 106007	14-3 18
205	Anti-rheumatic in SARS-CoV-2: benefit or risk?. 2020 ,	10
204	Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?. 2020 , 142, 109815	106
203	Drug repurposing against COVID-19: focus on anticancer agents. 2020 , 39, 86	44
202	(Iso)Quinoline-Artemisinin Hybrids Prepared through Click Chemistry: Highly Potent Agents against Viruses. 2020 , 26, 12019-12026	10
201	Systemic lupus erythematosus and risk of infection. 2020 , 16, 527-538	12
200	Cancer and COVID-19: Unmasking their ties. 2020 , 88, 102041	48
199	Hydroxychloroquine for the Prevention of Covid-19 - Searching for Evidence. 2020 , 383, 585-586	65

198	Severe pneumonia in Chinese patients with systemic lupus erythematosus. 2020 , 29, 735-742		7
197	COVID-19: an unexpected indication for anti-rheumatic therapies?. 2020 , 59, 1200-1203		5
196	Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials. 2020 , 13, e008688		10
195	Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review. 2020 , 26, 979-987		33
194	Molecular Targets in the Chemotherapy of Coronavirus Infection. 2020 , 85, 523-530		6
193	Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19. 2020 , 132, 604-613		19
192	Risk Factors and Prevention of <i>Pneumocystis jirovecii</i> Pneumonia in Patients With Autoimmune and Inflammatory Diseases. 2020 , 158, 2323-2332		15
191	Treatment of COVID 19-Repurposing drugs commonly used in dermatology. 2020 , 33, e13829		3
190	Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. 2020 , 60, 32		24
189	Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106054	14.3	168
188	New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105938	14.3	663
187	Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs. 2020 , 40, 825-826		28
186	Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105932	14.3	568
185	Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19. 2020 , 18, 1119-1133		16
184	Progress in the Research and Development of Anti-COVID-19 Drugs. 2020 , 8, 365		9
183	Drug repurposing: Discovery of troxipide analogs as potent antitumor agents. 2020 , 202, 112471		8
182	Clinical characteristics and risk factors of infection in patients with systemic lupus erythematosus: A systematic review and meta-analysis of observational studies. 2020 , 50, 1022-1039		15
181	Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges. 2020 , 25, 1786-1792		4

180	Application of Artificial Intelligence in COVID-19 drug repurposing. 2020 , 14, 1027-1031		75
179	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105924	14.3	2763
178	Hydroxychloroquine may reduce risk of Pneumocystis pneumonia in lupus patients: a Nationwide, population-based case-control study. 2020 , 20, 112		9
177	Chloroquine for the 2019 novel coronavirus SARS-CoV-2. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105923	14.3	260
176	COVID-19: A review of therapeutics under investigation. 2020 , 1, 231		20
175	The epidemiology, diagnosis and treatment of COVID-19. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105955	14.3	486
174	Chloroquine as a prophylactic agent against COVID-19?. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105980	14.3	24
173	Chloroquine and its derivatives in the management of COVID-19: A scoping review. 2020 , 40, 80-95		4
172	Médicaments rhumatologiques pour le traitement de l'infection par le COVID-19. 2020 , 87, 150-152		2
171	Hydroxychloroquine in Covid-19: Does the end justify the means?. 2020 , 68, 81-82		1
170	Is Coronavirus Disease 2019 (COVID-19) seen less in countries more exposed to Malaria?. 2020 , 140, 109756		9
169	Old and new antirheumatic drugs for the treatment of COVID-19. 2020 , 87, 195-197		11
168	COVID-19 outbreak: Migration, effects on society, global environment and prevention. 2020 , 728, 138882		636
167	When fear and misinformation go viral: Pharmacists' role in deterring medication misinformation during the 'infodemic' surrounding COVID-19. 2021 , 17, 1954-1963		80
166	Chloroquine, Hydroxychloroquine and Hearing Loss: A Study in Systemic Lupus Erythematosus Patients. 2021 , 131, E957-E960		2
165	Prevalence of hydroxychloroquine retinopathy using 2018 Royal College of Ophthalmologists diagnostic criteria. 2021 , 35, 343-348		7
164	Revisiting pharmacological potentials of Nigella sativa seed: A promising option for COVID-19 prevention and cure. 2021 , 35, 1329-1344		19
163	Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing. 2021 , 46, 17-27		14

162	Dysbiosis in the oral microbiomes of anti-CCP positive individuals at risk of developing rheumatoid arthritis. 2021 , 80, 162-168	21
161	Novel coronavirus 2019 (COVID-19) pandemic outbreak: A comprehensive review of the current literature. 2021 , 22, 106-113	6
160	A comparative analysis for anti-viral drugs: Their efficiency against SARS-CoV-2. 2021 , 90, 107232	16
159	Therapeutic drugs for SARS-CoV-2 treatment: Current state and perspective. 2021 , 90, 107228	12
158	Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial. 2021 , 174, 344-352	36
157	A Revisit to the Research Updates of Drugs, Vaccines, and Bioinformatics Approaches in Combating COVID-19 Pandemic. 2020 , 7, 585899	6
156	COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease. 2021 , 232, 13-36	26
155	Alternative treatment of fungal infections: Synergy with non-antifungal agents. 2021 , 64, 232-244	3
154	Recent progress of antiviral therapy for coronavirus disease 2019. 2021 , 890, 173646	16
153	Hydroxychloroquine in the post-COVID-19 era: will this pandemic upset decades of clinical practice?. 2021 , 40, 1649-1657	1
152	RNA dependent RNA polymerase (RdRp) as a drug target for SARS-CoV2. 2021 , 1-13	10
151	SARS-CoV-2 infection and smoking: What is the association? A brief review. 2021 , 19, 1654-1660	3
150	Ongoing Clinical Trials and the Potential Therapeutics for COVID-19 Treatment. 2021 , 27-89	
149	Single-Cell Gene Regulatory Network Analysis Reveals Potential Mechanisms of Action of Antimalarials Against SARS-CoV-2. 2021 , 88-94	
148	Molecular mechanisms and pharmacological interventions in the replication cycle of human coronaviruses. 2020 , 44, e20200212	6
147	Insights of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) pandemic: a current review. 2021 , 23, 5	8
146	Social inequalities and health crises: the forgotten and leave them behind. 2021 , 14, 35-45	1
145	Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19). 2021 , 27, 115-126	7

144	Synthesis and antiviral activity of a series of novel quinoline derivatives as anti-RSV or anti-IAV agents. 2021 , 214, 113208	3
143	Chloroquine, an Anti-Malaria Drug as Effective Prevention for Hantavirus Infections. 2021 , 11, 580532	0
142	Inhibition of Chikungunya Virus Infection by 4-Hydroxy-1-Methyl-3-(3-morpholinopropanoyl)quinoline-2(1)-one (QVIR) Targeting nsP2 and E2 Proteins. 2021 , 6, 9791-9803	2
141	BCG Vaccine-Induced Trained Immunity and COVID-19: Protective or Bystander?. 2021 , 14, 1169-1184	5
140	Drug design and repurposing with DockThor-VS web server focusing on SARS-CoV-2 therapeutic targets and their non-synonym variants. 2021 , 11, 5543	24
139	Current diagnostic and therapeutic strategies for COVID-19. 2021 , 11, 129-137	5
138	Repurposing Chloroquine Against Multiple Diseases With Special Attention to SARS-CoV-2 and Associated Toxicity. 2021 , 12, 576093	10
137	SARS-CoV-2 Therapy: Old Drugs as New Interventions. 2021 , 2, 142-150	1
136	Binding ability of arginine, citrulline, -acetyl citrulline and thiocitrulline with SARS COV-2 main protease using molecular docking studies. 2021 , 10, 28	1
135	Treatment profiles and clinical outcomes of COVID-19 patients at private hospital in Jakarta. 2021 , 16, e0250147	11
134	Effect of hydroxychloroquine on angiographic progression in routine treatment of Takayasu arteritis. 2021 , 31, 1135-1141	2
133	Therapeutic approaches to coronavirus infection according to "One Health" concept. 2021 , 136, 81-88	1
132	Drug Repurposing in Medical Mycology: Identification of Compounds as Potential Antifungals to Overcome the Emergence of Multidrug-Resistant Fungi. 2021 , 14,	6
131	Chloroquine Ingestion to Prevent SARS-CoV-2 Infection: A Report of Two Cases. 2021 , 5, 234-238	
130	Testing the feasibility of operationalizing a prospective, randomized trial with remote cardiac safety EKG monitoring during a pandemic. 2021 , 1	1
129	COVID-19 and Diabetes Mellitus: A Complex Interplay. 2021 , 15, 512-523	0
128	Novel coronavirus 2019 (COVID-19) pandemic outbreak: A comprehensive review of the current literature. 2021 , 22, 106-113	0
127	Anti-Cancer Potential of Some Commonly Used Drugs. 2021 , 27, 4530-4538	2

126	Crimean-Congo Hemorrhagic Fever Virus: Current Advances and Future Prospects of Antiviral Strategies. 2021 , 13,	3
125	The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review. 2021 , 10, 100085	5
124	Coronavirus Disease 2019 (COVID-19): Current Situation and Therapeutic Options. 2021 , 2, 481-491	10
123	Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy. 2021 , 138, 111518	25
122	Impact of Inflammatory Response Modifiers on the Incidence of Hospital-Acquired Infections in Patients with COVID-19. 2021 , 10, 1407-1418	2
121	Reinforcing our defense or weakening the enemy? A comparative overview of defensive and offensive strategies developed to confront COVID-19. 2021 , 53, 508-541	
120	A review on the pharmacokinetic properties and toxicity considerations for chloroquine and hydroxychloroquine to potentially treat coronavirus patients. 2021 , 1-12	2
119	Computational assessment of select antiviral phytochemicals as potential SARS-Cov-2 main protease inhibitors: molecular dynamics guided ensemble docking and extended molecular dynamics. 2021 , 9, 44	6
118	Research and effectiveness of anti-viral drugs against COVID-19; global public intervention to prevent coronavirus and to improve human health. 2021 , 28, 4082-4088	1
117	Antimalarial-induced retinal toxicity. 2021 , 28, 132-132	0
116	The future is now: our experience starting a remote clinical trial during the beginning of the COVID-19 pandemic. 2021 , 22, 603	1
115	Kidney injury in COVID-19 patients, drug development and their renal complications: Review study. 2021 , 142, 111966	5
114	Biomimetic properties and estimated in vivo distribution of chloroquine and hydroxy-chloroquine enantiomers.. 2021 , 9, 151-165	
113	Drugs for the Treatment of COVID-19. 2021 , 193-204	
112	Hydroxychloroquine and COVID-19: a Rheumatologist's Take on the Lessons Learned. 2021 , 21, 5	4
111	Are Patients with Asthma and Chronic Obstructive Pulmonary Disease Preferred Targets of COVID-19?. 2021 , 84, 22-34	6
110	Hydroxychloroquine in COVID-19: therapeutic promises, current status, and environmental implications. 2021 , 28, 40431-40444	13
109	Repurposing clinical drugs is a promising strategy to discover drugs against Zika virus infection. 2021 , 15, 404-415	4

108	COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine. 2020 , 35, 685-698	6
107	Review of trials currently testing treatment and prevention of COVID-19. 2020 , 26, 988-998	57
106	Development of a Physiologically-Based Pharmacokinetic (PBPK) Model of Nebulized Hydroxychloroquine for Pulmonary Delivery to COVID-19 Patients. 2021 , 71, 250-256	5
105	Hydroxychloroquine and COVID-19: Lack of Efficacy and the Social Construction of Plausibility. 2020 , 27, e573-e583	3
104	Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model. 2015 , 96, 3484-3492	94
103	Molecular Mechanism of Action of Repurposed Drugs and Traditional Chinese Medicine Used for the Treatment of Patients Infected With COVID-19: A Systematic Scoping Review.	1
102	Arbidol treatment with reduced mortality of adult patients with COVID-19 in Wuhan, China: a retrospective cohort study.	9
101	The Role of Hydroxychloroquine in the Age of COVID-19: A Periodic Systematic Review and Meta-Analysis.	17
100	Review and methodological analysis of trials currently testing treatment and prevention options for COVID-19 globally.	1
99	Assessment of Hydroxychloroquine and Chloroquine Safety Profiles: A Systematic Review and Meta-Analysis. 2020 ,	5
98	COVID-19 and lung cancer: risks, mechanisms and treatment interactions. 2020 , 8,	24
97	CORONAVIRUS DISEASE 2019 (COVID-19): A RHEUMATOLOGIST'S THOUGHTS. 2020 , 58, 123-132	27
96	Exploring Repurposing Potential of Existing Drugs in the Management of COVID-19 Epidemic: A Critical Review. 2020 , 12, 463-471	4
95	Validation of a liquid chromatography tandem mass spectrometry method for the simultaneous determination of hydroxychloroquine and metabolites in human whole blood. 2020 , 58, 2047-2061	4
94	A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2. 2021 , 13, e13105	32
93	Chloroquine use improves dengue-related symptoms. 2013 , 108, 596-9	41
92	Pharmacological therapies for patients with human coronavirus infections: a rapid systematic review. 2020 , 25, 3517-3554	2
91	Chloroquine use improves dengue-related symptoms. 2013 , 108, 596-599	69

90	COVID-19 and the Rationale for Pharmacotherapy: A South African Perspective. 2020 , 2, 11	3
89	Facts and Myths: Efficacies of Repurposing Chloroquine and Hydroxychloroquine for the Treatment of COVID-19. 2020 , 21, 1703-1721	5
88	COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development. 2020 , 8, 323-353	8
87	The effect of COVID-19 on global population and its fatality rate: Retrospective study by online database. 2020 , 72, 13-16	3
86	A Generalized Overview of SARS-CoV-2: Where Does the Current Knowledge Stand?. 2020 , 17, em251	7
85	Hydroxychloroquine in COVID-19 Patients: Pros and Cons. 2020 , 11, 597985	13
84	Papain-Like Proteases as Coronaviral Drug Targets: Current Inhibitors, Opportunities, and Limitations. 2020 , 13,	16
83	Escherichia coli-host macrophage interactions in the pathogenesis of inflammatory bowel disease. 2014 , 20, 8751-63	17
82	Wide Applications of Chloroquine Other Than Antimalarial. 2020 , 11, 251-281	1
81	Anti-hepatitis C virus potency of a new autophagy inhibitor using human liver slices model. 2016 , 8, 902-14	5
80	The Role of Hydroxychloroquine in COVID-19 Treatment: A Systematic Review and Meta-Analysis. 2020 , 49,	7
79	Chloroquine and COVID-19 - a potential game changer?. 2020 ,	14
78	Rapid Forecasting of Pandemic Outbreak Using Machine Learning. 2021 , 59-73	0
77	Systemic Lupus Erythematosus. 2013 , 183-191	
76	The Chemical Sciences' Advances on Coronavirus Disease 2019 (COVID-19). 2020 , 5, 179-184	
75	Pharmacological Aspects and 'Clues for the Rational Use of'Chloroquine / ydroxychloroquine Facing the Therapeutic Challenges' of COVID-19 Pandemic. 2020 , 2, 28-34	2
74	Les anti-inflammatoires et SARS-CoV-2 (COVID-19). 2020 , 21, 47-51	
73	Viral Dynamics Matter in COVID-19 Pneumonia: the success of early treatment with hydroxychloroquine and azithromycin in Lebanon.	

- 72 Coronavirus infection: principles of ethyotropic chemotherapy. **2020**, 18-39
- 71 The COVID-19 Pandemic: Are There Any Impacts on Sustainability?. **2021**, 13, 11956 2
- 70 COVID-19 THERAPY: WHAT HAVE WE LEARNED IN 8 MONTHS?. **2020**, 59, 207-225 0
- 69 Strategies for search of pharmacological drugs against SARS-CoV-2 on the base of studying the structural-genetic features of coronaviruses SARS-CoV, MERS-CoV and SARS-CoV-2. **2020**, 18, 269-296 0
- 68 Therapeutic options in SARS-CoV-2 infection. **2020**, 4, 14
- 67 Medicamentos versátiles: buscando balas mágicas. **2020**, 33, 32-43
- 66 Perspectives on repositioning chloroquine and hydroxychloroquine for the treatment of Covid-19. **2020**, 20, 4-9 1
- 65 Guía COVID-19 para la atención del paciente crítico con infección por SARS-coV-2 Colegio Mexicano de Medicina Crítica. **2020**, 33, 7-42 5
- 64 Hydroxychloroquine: the story of one drug during the COVID-19 pandemic. **2020**, 123, 74
- 63 Coronavirus Disease-2019 Pandemic: Hopes Ride High on Targeting Known Drugs against Unknow. **2020**, 52, 75-78 0
- 62 THE ROLE OF HYDROXYCHLOROQUINE IN THE TREATMENT OF HIV AND COVID-19: A REVIEW.. **2020**, 9, 20-29
- 61 Basic Critical Care for Management of COVID-19 Patients: Position Paper of Indian Society of Critical Care Medicine, Part-I. **2020**, 24, S244-S253 0
- 60 Emerging importance of nanotechnology-based approaches to control the COVID-19 pandemic; focus on nanomedicine iterance in diagnosis and treatment of COVID-19 patients. **2021**, 67, 102967 7
- 59 A Review on Current Scenario of 2019-nCoV and Its Treatments. **2020**, 1, 1-15
- 58 TREATMENT PROFILES AND CLINICAL OUTCOMES OF COVID-19 PATIENTS AT PRIVATE HOSPITAL IN JAKARTA.
- 57 Farmacoterapia aplicada a COVID-19. 58-81
- 56 The Role of Hydroxychloroquine in COVID-19 Treatment: A Systematic Review and Meta-Analysis. **2020**, 1
- 55 Hydroxychloroquine in Dermatology and Beyond: Recent Update. **2020**, 11, 453-464 5

54	Real Clinical Practice and Therapeutic Management Following COVID-19 Crisis in two Hospitals in Iran: A Statistical and Conceptual View. 2020 , 19, 112-121	
53	Therapeutic strategies against COVID-19. 2020 , 91, e2020038	2
52	Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients-a systematic review and meta-analysis of randomized controlled trials. 2021 , 11, 93-107	9
51	Roles of host mitochondria in the development of COVID-19 pathology: Could mitochondria be a potential therapeutic target?. 2021 , 2, 38	2
50	Antimalarial treatment and minimizing prednisolone are associated with lower risk of infection in SLE: a 24-month prospective cohort study. 2021 , 1	0
49	Safety of Chloroquine or Hydroxychloroquine Plus Azithromycin for the Treatment of COVID-19 Patients in Burkina Faso: An Observational Prospective Cohort Study. 2021 , 17, 1187-1198	0
48	An aromatic imidazoline derived from chloroquinoline triggers cell cycle arrest and inhibits with high selectivity the Trypanosoma cruzi mammalian host-cells infection. 2021 , 15, e0009994	0
47	Hydroxychloroquine in dermatology and beyond: Recent update. 2020 , 11, 453	10
46	Infecç�o no paciente com l�pus eritematoso sist�mico. 2015 , 40-47	0
45	Ganglioside binding domains in proteins: Physiological and pathological mechanisms.. 2022 , 128, 289-324	1
44	The emergence, dynamics and significance of SARS-CoV-2 variants.. 2022 , 100962	1
43	Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines.. 2022 , 54, 524-540	17
42	Mechanism of Blood-Heart-Barrier Leakage: Implications for COVID-19 Induced Cardiovascular Injury.. 2021 , 22,	1
41	Mechanism of Action of Small-Molecule Agents in Ongoing Clinical Trials for SARS-CoV-2: A Review.. 2022 , 13, 840639	1
40	The Dark Side of the COVID-19 Treatments on Infection.. 2022 , 14, e2022021	1
39	Quantitative analysis of favipiravir and hydroxychloroquine as FDA-approved drugs for treatment of COVID-19 using synchronous spectrofluorimetry. Application to pharmaceutical formulations and biological fluids.. 2022 ,	1
38	Associations between inflammation-related LL-37 with subgingival microbial dysbiosis in rheumatoid arthritis patients.. 2022 , 1	1
37	COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?. 2022 , 179, 106201	3

- 36 COVID-19 Pandemic: Outbreak, Potential Vaccines And Medications. **2021**, 10,
- 35 Quantitation of SARS-CoV-2 neutralizing antibodies with a virus-free, authentic test. 0
- 34 DataSheet_1.pdf. **2020**,
- 33 DataSheet_2.pdf. **2020**,
- 32 Image_1.pdf. **2020**,
- 31 DataSheet_1.pdf. **2020**,
- 30 DataSheet_2.pdf. **2020**,
- 29 Molecular Docking and ADMET Prediction of Natural Compounds towards SARS Spike Glycoprotein-Human Angiotensin-Converting Enzyme 2 and SARS-CoV-2 Main Protease. **2021**, 76, 453-459 2
- 28 Antimicrobials in COVID-19: strategies for treating a COVID-19 pandemic.. **2022**, 0
- 27 Increase in Ca²⁺-Activated cAMP/PKA Signaling Prevents Hydroxychloroquine-Induced Bradycardia of the Cardiac Pacemaker. **2022**, 13, 1
- 26 Therapeutic approaches and vaccination in fighting COVID-19 infections: A review.. **2022**, 27, 101619 0
- 25 Topical Repute on Artificial Intelligence-Based Approaches in COVID-19 Supervision. **2022**, 180-210
- 24 Journey of Chloroquine/ Hydroxychloroquine in the management of COVID-19. **2022**, 110-116
- 23 Myth surrounding the FDA disapproval of hydroxychloroquine sulfate and chloroquine phosphate as drugs for coronavirus disease 2019. **2022**, 153-168 0
- 22 COVID- 19: disease, progress, control and their relation with sex. **2022**, 32, 1-10
- 21 Present therapeutic and diagnostic approaches for SARS-CoV-2 infection. **2022**, 421-449
- 20 The Oral Microbiome and Its Role in Systemic Autoimmune Diseases: A Systematic Review of Big Data Analysis. 5, 1
- 19 Molecular docking analysis of Adhatoda Vasica withThromboxane A2 receptor (TXA2R) (6IIU) and Antiviral molecules for possible dengue complications. **2022**, 22,

18	An observational, retrospective, comprehensive pharmacovigilance analysis of hydroxychloroquine-associated cardiovascular adverse events in patients with and without COVID-19.	0
17	Honey as an Adjuvant in the Treatment of COVID-19 Infection: A Review. 2022 , 12, 7800	1
16	Autophagy in SARS-CoV-2 infection. 2022 , 100596	0
15	Adsorption of Selected Molecules on (TiO ₂) ₂₀ Nano-Clusters: A Density-Functional-Theory Study. 2022 , 2, 124-145	1
14	A Syntenin Inhibitor Blocks Endosomal Entry of SARS-CoV-2 and a Panel of RNA Viruses. 2022 , 14, 2202	0
13	Study of chloroquine susceptibility potential of plants using pseudomonas aeruginosa as in vitro model. 2022 , 12,	0
12	The failure of drug repurposing for COVID-19 as an effect of excessive hypothesis testing and weak mechanistic evidence. 2022 , 44,	0
11	An Overview of Repurposed Drugs for Potential COVID-19 Treatment. 2022 , 11, 1678	0
10	A systematic review of gene editing clinical trials.	0
9	Hydroxychloroquine for treatment of non-hospitalized adults with COVID -19: A meta-analysis of individual participant data of randomized trials.	0
8	New Iron Twist to Chloroquine-Upgrading Antimalarials with Immunomodulatory and Antimicrobial Features. 2023 , 66, 2084-2101	0
7	Antiviral Drugs for the Control of Pandemic Influenza Virus. 2008 , 37, 518-524	1
6	Novel Tetrahydroisoquinoline-Based Heterocyclic Compounds Efficiently Inhibit SARS-CoV-2 Infection In Vitro. 2023 , 15, 502	0
5	Risk of Bloodstream Infection in Patients with Systemic Lupus Erythematosus Exposed to Prolonged Medium-to-High-Dose Glucocorticoids. 096120332311607	0
4	Potential use of renin-angiotensin-aldosterone system inhibitors to reduce COVID-19 severity. 2023 , 42, 373-383	1
3	Knowledge, Concept on severe Acute Respiratory Syndrome Coronavirus-2(SARS-CoV-2). A Review of the Literature and Future perspective. 2023 , 441-446	0
2	The HAVEN studyHydroxychloroquine in ANCA vasculitis evaluation¶ multicentre, randomised, double-blind, placebo-controlled trial: study protocol and statistical analysis plan. 2023 , 24,	0
1	Recent spectrophotometric and electroanalytical methods used for the determination of quinoline-based compounds.	0

